MD Magazine: African Americans, Hispanics Poorly Represented in Asthma Clinical Trials
By Cecilia Pessoa Gingerich
By While African American and Hispanic patients are disproportionately affected by severe asthma, these patients are poorly represented among participants in clinical trials of monoclonal antibody treatments for asthma, according to a recent study.
The results were presented at the annual meeting of the American College of Asthma, Allergy and Immunology (ACAAI) in Seattle, Washington, by study authors Susamita Kesh, MD, Children’s Mercy Kansas City, and Bridgette Jones, MD, MS, an allergist-immunologist at Children's Mercy Kansas City and associate professor of pediatrics, University of Missouri, Kansas City School of Medicine.
Many studies have shown racial or ethnic discrepancies in how asthma affects different populations. One study presented earlier this year showed that African Americans have a 2.5-fold greater chance of developing asthma.The investigators from Kansas City wanted to identify how many trials for asthma treatments include racial/ethnic data, as well as determine how well represented African American and Hispanic populations were in those studies.
“Future trials to establish asthma therapeutic efficacy/ safety for biologic agents to treat severe asthma should be conducted among better representative samples of patients with severe asthma,” wrote Kesh and Jones.
Read the full story via MD Magazine
Learn more about Allergy, Asthma, and Immunology at Children's Mercy